Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer ; volume:41 ; number:7 ; day:31 ; month:5 ; year:2023 ; pages:1837-1845 ; date:7.2023
World journal of urology ; 41, Heft 7 (31.5.2023), 1837-1845, 7.2023
- Creator
-
Hoogstraten, Lisa M. C. van
Man, Calvin C. O.
Witjes, J. Alfred
Meijer, Richard P.
Mulder, Sasja F.
Smilde, Tineke J.
Ripping, Theodora M.
Kiemeney, Lambertus A.
Aben, Katja K. H.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00345-023-04443-7
- URN
-
urn:nbn:de:101:1-2023102409072240219906
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hoogstraten, Lisa M. C. van
- Man, Calvin C. O.
- Witjes, J. Alfred
- Meijer, Richard P.
- Mulder, Sasja F.
- Smilde, Tineke J.
- Ripping, Theodora M.
- Kiemeney, Lambertus A.
- Aben, Katja K. H.
- SpringerLink (Online service)
Other Objects (12)
Comparison of responses to neoadjuvant and adjuvant chemotherapies in muscle-invasive bladder cancer
Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers
Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer
Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival
Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial
Proteomics research on muscle-invasive bladder transitional cell carcinoma
The natural history of secondary muscle-invasive bladder cancer
Bladder Preservation with Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for the Treatment of Muscle-invasive Carcinoma of the Bladder: A Single-Center Experience
Stromal proteome expression profile and muscle-invasive bladder cancer research
Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer
Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival
Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients
Comparison of responses to neoadjuvant and adjuvant chemotherapies in muscle-invasive bladder cancer
Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers
Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer
Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival
Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial
Proteomics research on muscle-invasive bladder transitional cell carcinoma
The natural history of secondary muscle-invasive bladder cancer
Bladder Preservation with Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for the Treatment of Muscle-invasive Carcinoma of the Bladder: A Single-Center Experience
Stromal proteome expression profile and muscle-invasive bladder cancer research
Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer
Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival
Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients
Comparison of responses to neoadjuvant and adjuvant chemotherapies in muscle-invasive bladder cancer
Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers
Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer
Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival
Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial
Proteomics research on muscle-invasive bladder transitional cell carcinoma
The natural history of secondary muscle-invasive bladder cancer
Bladder Preservation with Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for the Treatment of Muscle-invasive Carcinoma of the Bladder: A Single-Center Experience
Stromal proteome expression profile and muscle-invasive bladder cancer research
Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer
Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival